FindTrial
Sign In

Revusiran (ALN-TTRSC)

DRUG2 trials

Sponsors

Alnylam Pharmaceuticals

Conditions

Amyloid NeuropathiesAmyloid Neuropathies, FamilialAmyloidosis, HereditaryAmyloidosis, Hereditary, Transthyretin-RelatedFamilial Transthyretin Cardiac AmyloidosisTTR-mediated AmyloidosisTransthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Phase 2

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
CompletedNCT02292186
Alnylam PharmaceuticalsTTR-mediated Amyloidosis
Start: 2014-10-31End: 2017-02-22Updated: 2020-07-09

Phase 3

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
CompletedNCT02319005
Alnylam PharmaceuticalsAmyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Hereditary +3
Start: 2014-12-31End: 2017-03-30Updated: 2018-07-18

Related Papers

Ligand Conjugated Antisense Oligonucleotide for the Treatment of Transthyretin Amyloidosis: Preclinical and Phase 1 Data
ESC Heart Failure2020-12-0785 citations
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
Cardiovascular Drugs and Therapy2020-02-15101 citations